160 HEALTH (02656) has announced that the Group expects to achieve an adjusted net profit (a non-IFRS measure) between RMB 3 million and RMB 5 million for the fiscal year ending December 31, 2025. This compares to an adjusted net loss (a non-IFRS measure) of RMB 31.5 million for the fiscal year ended December 31, 2024. This marks the Group's first full-year profit on an adjusted net profit (non-IFRS) basis. The turnaround to an adjusted net profit for the current year is primarily attributable to the combined effect of the following factors: (i) a year-on-year increase in revenue, leading to a slight improvement in gross profit; and (ii) a significant reduction in total operating expenses (including sales and marketing, research and development, and administrative expenses) achieved through refined management and continuous enhancement of operational efficiency.